BCMA is selectively induced at the time of plasma cell differentiation and is almost absent on immature and memory B cells (Avery et al., 2003; Chiu et al., 2007). The communication between BCMA and its ligand APRIL and BAFF is required for the maintenance of long-lived plasma cells (O'Connor et al., 2004; Peperzak et al., 2013).
BCMA is a perfect target for cancers of plasma cells as it is not present in other important organs. Dozens of BCMA-targeting therapies, such as antibody-drug conjugate, Bi-specific antibodies, and chimeric antigen receptor T (CAR-T) cells are presently being created and tested clinically. Bluebird and Celgene’s bb2121 is leading the pack. A phase I multi-center clinical trial has established a striking 80% response rate in multiple myeloma patients. If these methods are effectively established, it will bring multiple myeloma patients a much-needed option beyond Elotuzumab (anti-SLAMF7) and Daratumumab (anti-CD38antibody).
The interactions between BAFF/APRIL and their receptors are selective. It should be noted that BCMA can interact with APRIL as well as BAFF (Bolkun et al., 2016). However, the affinity of APRIL-BCMA interaction is considerably higher when compared to BAFF-BCMA binding (Bossen and Schneider, 2006).
ACROBiosystems offers a wide-ranging panel of BCMA proteins, including the unique biotinylated BCMA (Cat. No. BC7-H82F0) and the monomeric BCMA (Cat. No. BCA-H522y). The company also provides-BCMA related proteins, for example, BAFF and BAFFR proteins.
Product Highlight
Figure 1. Immobilized Human BAFF, Fc Tag (Cat. No. BAF-H4268) at 5 μg/mL (100 μL/well) can bind Biotinylated Human BCMA, Fc Tag (Cat. No. BC7-H82F0) with a linear range of 0.12–1.95 ng/mL.
Figure 2. The purity of Human BCMA, His Tag (Cat. No. BCA-H522y) is greater than 93% as determined by SEC-HPLC.
ACROBiosystems provides a range of ready-to-use biotinylated proteins using their in-house developed labeling techniques, which offer high bioactivity and less batch-to-batch difference. Furthermore, they also provide FITC-labeled BCMA and BAFF proteins.
BCMA Product List
Other Relevant Products
Other Multiple Myeloma Targets
References
- Avery et al., 2004, J Clin Invest. 112, 286–297.
- Chiu et al., 2007, Blood 109, 729–739.
- O’Connor et al., 2004, J. Exp. Med. 199, 91–98.
- Peperzak et al., 2013, Nat. Immunol. 14, 290–297.
- Bolkun et al., 2016, J. Cancer 7, 1979–1983.
- Bossen and Schneider, 2006, Semin. Immunol. 18, 263–275.
About ACROBiosystems
![]()
ACROBiosystems is a cornerstone enterprise of the pharmaceutical and biotechnology industries. Their mission is to help overcome challenges with innovative tools and solutions from discovery to the clinic. They supply life science tools designed to be used in discovery research and scalable to the clinical phase and beyond. By consistently adapting to new regulatory challenges and guidelines, ACROBiosystems delivers solutions, whether it comes through recombinant proteins, antibodies, assay kits, GMP-grade reagents, or custom services. ACROBiosystems empower scientists and engineers dedicated towards innovation to simplify and accelerate the development of new, better, and more affordable medicine.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.